Navigation Links
MAP Pharmaceuticals Reports Positive Results From Phase 2a Clinical Trial of Combination Therapy in Adult Asthmatics
Date:4/7/2008

ines. The company applies its proprietary inhalation technologies to enhance the therapeutic benefits and commercial attractiveness of proven drugs while minimizing risk by capitalizing on their known safety, efficacy and commercialization history. MAP Pharmaceuticals has two drug candidates, Unit Dose Budesonide and MAP0004, in late stage development for the potential treatment of pediatric asthma and migraine respectively. MAP Pharmaceuticals' pipeline also includes a drug candidate in early clinical development for the treatment of asthma and chronic obstructive pulmonary disease.

Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.

Forward-Looking Statements

In addition to statements of historical facts or statements of current conditions, this press release contains forward-looking statements, including with respect to the further development of MAP0005 and the potential application of MAP Pharmaceuticals' technologies to additional product candidates. Actual results may differ materially from current expectations based on risks and uncertainties affecting the Company's business, including, without limitation, risks and uncertainties relating to the development and commercialization of product candidates incorporating MAP Pharmaceuticals' technologies. The reader is cautioned not to unduly rely on the forward- looking statements contained in this press release. MAP Pharmaceuticals expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law. Additional information on potential factors that could affect MAP Pharmaceuticals' results and other risks and uncertainties are detailed in its Annual Report on Form 10K, filed with the SEC on March 20, 2008, available at http://edgar.sec.gov.


'/>"/>
SOURCE MAP Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Transdel Pharmaceuticals Advances Lead Topical Pain Drug into Phase 3 Program
2. VIA Pharmaceuticals Announces Updated DSMB Safety Results for VIA-2291 Ongoing Phase 2 Clinical Program
3. Rib-X Pharmaceuticals to Present at 10th Annual Superbugs & Superdrugs Conference
4. EnVivo Pharmaceuticals Announces Initiation of Clinical Safety and Biomarker Study of Alpha-7 Nicotinic Agonist, EVP-6124, in Patients with Schizophrenia
5. ISTA Pharmaceuticals Announces Results of Clinical Trial of Xibrom(TM) QD (Once-Daily) Formulation
6. Monogram Biosciences Provides Progenics Pharmaceuticals with HIV Assays for Use in Clinical Trials
7. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
8. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
9. Rexinoid Developed by NuRx Pharmaceuticals Shows Promise in Prevention, Treatment of Lung, Breast Cancer, Paper in Clinical Cancer Research Reports
10. Anacor Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial of AN2728 in Psoriasis Patients
11. NuRx Pharmaceuticals Doses First Patient in Phase I Clinical Trial of First-in-Class RXR Agonist NRX4204
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... The global market for human vaccines ... of new vaccines. These new products and other ... The Kalorama information report examines the global market ... vaccines for diseases that are already vaccine-preventable. ... communities from diseases spread by person-to-person transmission. The ...
(Date:10/27/2014)... Calif. , Oct. 27, 2014  RenovoRx, a ... blood flow and delivery of fluids to selected sites ... Board of Directors has appointed Shaun Bagai ... of the RenovoRx Board of Directors. Bagai brings more ... industry. Bagai joined RenovoRx in June 2014 ...
(Date:10/27/2014)... 27, 2014  In the last few weeks, Ebola has gone ... to a worldwide crisis when a traveler to ... died, and two nurses were infected. While much of ... use of modern technology, such as electronic health records (EHRs), to ... This week, InformationWeek Healthcare Editor Alison Diana fills in ...
Breaking Medicine Technology:Vaccines 2014: World Market Analysis, Key Players, Trends, Pediatric and Adult Segments 2Vaccines 2014: World Market Analysis, Key Players, Trends, Pediatric and Adult Segments 3RenovoRx Board Names Shaun R. Bagai as CEO 2EHRs in the Age of Ebola: Discuss on InformationWeek 2EHRs in the Age of Ebola: Discuss on InformationWeek 3
... 2012 /PRNewswire-Asia/ -- China Kanghui Holdings (NYSE: ... leading domestic developer, manufacturer and marketer of orthopedic ... operating subsidiaries, Beijing Libeier Biology Engineering Research Institute ... Ltd, have received approvals from relevant PRC authorities ...
... MAPLE GROVE, Minn., Jan. 11, 2012  Snow tires? Check! ... Just like a car, you need to prepare your ... extreme temperature changes can result in skin that is ... brakes on severe dry skin before it starts with ...
Cached Medicine Technology:China Kanghui Holdings Renews High and New Technology Enterprises Status of Its PRC Operating Subsidiaries 2Don't Let Your Skin Take a Backseat As You Prepare for Winter 2Don't Let Your Skin Take a Backseat As You Prepare for Winter 3
(Date:10/30/2014)... Home Care Assistance – Halton/Peel Region ( ... senior care, is weighing in on a recent study ... study, performed by the University of Illinois, analyzed 88 ... a week-long period and observed how much time was ... examining the structural soundness of the white matter in ...
(Date:10/30/2014)... FL (PRWEB) October 30, 2014 ... Joint Commission Accredited teleradiology and specialty telemedicine solutions ... in addition to its existing teleradiology services at ... second opinion and expert telemedicine services, to the ... , As a result of this innovative partnership, ...
(Date:10/30/2014)... 2014 Victory Healthcare, a privately ... third quarter infection rates and patient satisfaction scores. ... of only two percent or less, and the ... 98 percent. , “We are delighted with our ... satisfaction scores,” said Robert Helms, chairman and CEO ...
(Date:10/30/2014)... HealthDay Reporter WEDNESDAY, Oct. ... chemical during pregnancy may have effects on genital development in ... baby boys born to moms with greater exposure to a ... -- the space between the genitals and anus. Anogenital distance ... of exposure to androgens ("male" hormones) during pregnancy. The ...
(Date:10/30/2014)... WEDNESDAY, Oct. 29, 2014 (HealthDay News) -- Americans, opinions ... political lines, a new study finds. Democratic voters ... (ACA), according to the researchers. Almost three-quarters of Democrats ... ACA. Thirty percent want Congress to implement the current ... of the ACA. Among Independent voters, one-third want ...
Breaking Medicine News(10 mins):Health News:Home Care Assistance – Halton/Peel Region, a Top Provider of In-Home Care, Responds to Study Linking Exercise to Healthier Senior Brains 2Health News:Home Care Assistance – Halton/Peel Region, a Top Provider of In-Home Care, Responds to Study Linking Exercise to Healthier Senior Brains 3Health News:USARAD HOLDINGS INC, SECONDOPINIONS.COM® Pioneers Specialty On-Demand Telemedicine And Second Opinion Service At Houston-Based, Mission Bend Freestanding ER Chain 2Health News:USARAD HOLDINGS INC, SECONDOPINIONS.COM® Pioneers Specialty On-Demand Telemedicine And Second Opinion Service At Houston-Based, Mission Bend Freestanding ER Chain 3Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 2Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 3Health News:Plastics' Chemical May Affect Baby Boys' Genital Development 2Health News:Plastics' Chemical May Affect Baby Boys' Genital Development 3Health News:Voters' Views on Obamacare Split Along Party Lines 2
... in the retina that is responsible for maintaining the health ... in a living retina for the first time. , The ... identify the onset of many diseases of the eye long ... issue of Investigative Ophthalmology and Visual Science ., "Our ...
... Tired of Putting Money in the Hands of Beauty Corporations ... / or Counseling to Remain Youthful? Now one does ... Never Before Published Secrets to Eternal Youth and Immortality, gives ... so that folks can attain and maintain the Age they ...
... Jade Goody who will be left behind without a ... Chantel "Chani" Christie who recently won the 2009 Martin ... is set to donate proceeds from her debut album ... star, Jade Goody. In addition, she also plans to ...
... facility already ahead of scheduleMARLTON, N.J., Feb. 25 ... exempt bonds from the New Jersey Health Care Facilities ... The bonds will be used to continue the financing ... our plan for finance in place and have met ...
... continued positive cash flow from operationsBOSTON, Feb. 25 ... a leader in radiology and medical image and ... for the fourth quarter and year ended December ... Financial Highlights Revenue : Total revenue for ...
... Feb. 25 Mesa Laboratories, Inc. (Nasdaq: ... manufacturing quality control applications, today announced the appointment of ... extensive experience to Mesa from his role as Chief ... Inc., a registered investment adviser based in New York ...
Cached Medicine News:Health News:'Dark cells' of living retina imaged for the first time 2Health News:'Dark cells' of living retina imaged for the first time 3Health News:What the Billion Dollar Beauty Industry Does Not Want Leaked: That One Can Actually Reverse Aging for Free by Moving Only to the Right. We Smell a Nobel. 2Health News:Chantel 'Chani' Christie Will Donate Proceeds From Her Top-Selling Debut Album 'My Dream' to the Children of Terminally Ill TV Star Jade Goody 2Health News:Virtua Health Takes Next Step for Continuing Hospital Construction 2Health News:AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31, 2008 2Health News:AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31, 2008 3Health News:AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31, 2008 4Health News:AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31, 2008 5Health News:AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31, 2008 6Health News:AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31, 2008 7Health News:AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31, 2008 8Health News:AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31, 2008 9Health News:AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31, 2008 10Health News:AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31, 2008 11Health News:AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31, 2008 12Health News:AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31, 2008 13Health News:AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31, 2008 14Health News:Mesa Labs Announces Appointment of New Director 2
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Cottle Tenaculum Skin Hook. 5 1/2" small, shallow curve....
Goldman single hook....
Needle tip electrode, davol advantage electrosurgical attachments, 33cm (with extendible outer sheath), non-sterile. These products are supplied non-sterile and must be sterilized before use. Reusabl...
Medicine Products: